Information Provided By:
Fly News Breaks for June 28, 2016
CYTX
Jun 28, 2016 | 08:35 EDT
Roth Capital analyst Joseph Pantginis says Cytori Therapeutics announced that its Celution system has received limited approval in Japan for the treatment of knee osteoarthritis, which he sees as an "important milestone" for the company as it opens up another avenue of potential revenue. The analyst continues to view Cytori as a leading regenerative medicine player and believes current valuations are attractive. He reiterates a Buy rating and $11 price target on the shares.
News For CYTX From the Last 2 Days
There are no results for your query CYTX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.